Journal
CANCERS
Volume 13, Issue 20, Pages -Publisher
MDPI
DOI: 10.3390/cancers13205069
Keywords
PLGA-NH2 nanoparticles; PET/MRI imaging; zirconium-89 labeling; in vivo tracking; primary amine; cell labeling
Categories
Funding
- Radboud Institute for Molecular Life Sciences (RIMLS)
- Dutch Cancer Society Young Investigator Grant [12493]
- Radboud Oncologie Fonds/Stichting Bergh in het Zadel, partner of Dutch Cancer Society [KUN2015-8106]
- Innovative Medicines Initiative 2 Joint Undertaking [116106]
- European Union
- EFPIA
- Netherlands Organisation for Scientific Research (NWO) [91617039]
- Dutch Cancer Society (KWF) [10099]
- European Research Council (ERC) starting grant (CoNQUeST) [336454]
- Proof of Concept (CoNQUeST) [713524]
- Netherlands organisation for scientific research NWO-TTW [14716]
- European Research Area Network on Cardiovascular Disease (ERA-CVD, SCAN) [2017T097]
- European Research Council (ERC) [336454] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
This study successfully demonstrated in vivo tracking of a small number of immune cells using zirconium-89-labeled poly(lactic-co-glycolic acid) nanoparticles, showing potential applications in various disease models.
Simple Summary: Immune cells are increasingly used for therapy in cancer and other diseases. To better understand immune-cell kinetics, cell-tracking with highly sensitive imaging modalities is required. The aim of this study was to develop a new strategy for the in vivo tracking of a small number of cells, using positron emission tomography (PET). We labeled poly(lactic-co-glycolic acid) nanoparticles containing a primary endcap (PLGA-NH2) with the radionuclide zirconium-89. The nanoparticles were characterized for size, polydispersity index, zetapotential and radiolabel retention. Subsequently, they were used for the ex vivo radiolabeling of a monocyte cell line (THP-1). We demonstrated that these radiolabeled monocyte cells can be traced in vivo in mouse tumor and infection models. The exponential growth of research on cell-based therapy is in major need of reliable and sensitive tracking of a small number of therapeutic cells to improve our understanding of the in vivo cell-targeting properties. In-111-labeled poly(lactic-co-glycolic acid) with a primary amine endcap nanoparticles ([In-111]In-PLGA-NH2 NPs) were previously used for cell labeling and in vivo tracking, using SPECT/CT imaging. However, to detect a low number of cells, a higher sensitivity of PET is preferred. Therefore, we developed Zr-89-labeled NPs for ex vivo cell labeling and in vivo cell tracking, using PET/MRI. We intrinsically and efficiently labeled PLGA-NH2 NPs with [Zr-89]ZrCl4. In vitro, [Zr-89]Zr-PLGA-NH2 NPs retained the radionuclide over a period of 2 weeks in PBS and human serum. THP-1 (human monocyte cell line) cells could be labeled with the NPs and retained the radionuclide over a period of 2 days, with no negative effect on cell viability (specific activity 279 +/- 10 kBq/10(6) cells). PET/MRI imaging could detect low numbers of [Zr-89]Zr-THP-1 cells (10,000 and 100,000 cells) injected subcutaneously in Matrigel. Last, in vivo tracking of the [Zr-89]Zr-THP-1 cells upon intravenous injection showed specific accumulation in local intramuscular Staphylococcus aureus infection and infiltration into MDA-MB-231 tumors. In conclusion, we showed that [Zr-89]Zr-PLGA-NH2 NPs can be used for immune-cell labeling and subsequent in vivo tracking of a small number of cells in different disease models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available